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SUMMARY
Background: Before the introduction of highly active antiretroviral therapy (HAART), CMV retinitis was a common
complication in patients with advanced HIV disease and the therapy was well established; it consisted of an induction phase to
control the infection with ganciclovir, followed by a lifelong maintenance phase to avoid or delay relapses. Methods: To determine
the safety of CMV maintenance therapy withdrawal in patients with immune recovery after HAART, 35 patients with treated CMV
retinitis, on maintenance therapy, with CD4+ cell count greater than 100 cells/mm3 for at least three months, but almost all
patients presented these values for more than six months and viral load < 30000 copies/mL, were prospectively evaluated for the
recurrence of CMV disease. Maintenance therapy was withdrawal at inclusion, and patients were monitored for at least 48 weeks
by clinical and ophthalmologic evaluations, and by determination of CMV viremia markers (antigenemia-pp65), CD4+/CD8+
counts and plasma HIV RNA levels. Lymphoproliferative assays were performed on 26/35 patients. Results: From 35 patients
included, only one had confirmed reactivation of CMV retinitis, at day 120 of follow-up. No patient returned positive antigenemia
tests. No correlation between lymphoproliferative assays and CD4+ counts was observed. Conclusion: CMV retinitis maintenance
therapy discontinuation is safe for those patients with quantitative immune recovery after HAART.
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INTRODUCTION
Cytomegalovirus (CMV) disease is an important cause of morbidity
and mortality in AIDS patients. In the pre-HAART era, CMV retinitis
was the most common HIV-associated retinopathy, occurring in 20-
40% of patients. Median time to progression was 47 to 104 days, mean
survival after diagnosis was six to 10 months, and indefinite intravenous
maintenance therapy was mandatory12. It leads to blindness in nearly
all untreated cases, has a high rate of short-term relapse and is strongly
associated with higher mortality1,10,15,17,34,38.
In the HAART era the incidence of CMV retinitis has declined
80% and survival after diagnosis has increased to over one year12.
After the development of HAART and subsequent successful HIV
suppression and sustained increase in CD4+ cell counts, studies
characterizing the effects of immune recovery on the course of
opportunistic infections were initiated. Studies addressing CMV
immune recovery were first published in 199824,31,44 targeting both
humoral6 and cellular responses23. Clinical studies followed,
demonstrating a low incidence of recurrence after withdrawal of
secondary prophylaxis in small samples4, 5,7,19,25,30,32,36,41,45,46.
The primary objective of the present open, non-randomized,
prospective and multicenter study is to evaluate the safety of the
withdrawal of secondary CMV prophylaxis in AIDS patients with
treated CMV retinitis who exhibit a sustained immunological response
to HAART (CD4+ count > 100 cells/mm3 and Viral Load < 30,000
copies/mm3), together with negative antigenemia tests for at least three
months. A second objective was to evaluate the utility of antigenemia
to monitor the recurrence of CMV disease, comparing the test results
with clinical and ophthalmologic data.
The protocol was designed in accordance with the requirements
for “Research Involving Human Subjects” in Brazil, and approved by
the Research Ethics Committee of each participating institution. All
patients provided written informed consent.
PATIENTS AND METHODS
Patients: Patients included in this protocol were originally treated
at the following facilities: 1. AIDS Day-Hospital, UNICAMP -
Campinas State University (Campinas, Brazil); 2. Day-Hospital, AIDS
Facility of Campinas City (Campinas, Brazil); 3. AIDS Day-Hospital,
IIER – Emilio Ribas Infectious Diseases Institute (São Paulo, Brazil);
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and 4. Day-Hospital, CRTA - Reference and Training Center for
Sexually Transmitted Diseases and AIDS (São Paulo, Brazil).
Inclusion criteria were: AIDS patients receiving HAART (two
nucleoside analogues plus one or two proteases inhibitors) with
previously treated CMV retinitis receiving secondary prophylaxis,
exhibiting sustained (quantitative) immune recovery, characterized by
CD4+ counts greater than 100 cells/mm3 for at least three months prior
to inclusion, with a viral load of less than 30,000 copies/mm3(2,6,10,33,41,45).
Exclusion criteria were: Patients with ganciclovir eye implants;
patients with any retinal condition that might interfere with their
ophthalmologic evaluation, such as Toxoplasma gondii retinitis or
cataract; patients with previous CMV retinal infection at perimacular
or peripapillary sites due to the risk of rapid visual loss; patients
requiring oncological chemotherapy and/or radiation therapy; patients
with any other condition constituting a high risk of death in the first
two months of the protocol; patients undergoing therapy for active
CMV disease were excluded until clinical status was stable; patients
unable to fully understand the terms of the consent to treatment.
Laboratory Techniques
CMV Antigenemia (pp65): Antigenemia (pp65) tests were
performed every 15 days for the first two months after ganciclovir
withdrawal and monthly thereafter.
The same in-house protocol and reagents were used in the
laboratories of all participating institutions to provide comparable
results3. The sequence described by VAN DER BIJ et al.42 was
performed with the following modifications: (1) Cells were fixed in
acetone; (2) Cell counts were considered to be the number of positive
cells per 3 x 105 cells13,28.
For the purposes of exclusion from the protocol and endpoints,
any positive test was considered, regardless of the number of positive
cells. Two consecutive positive tests were interpreted as persistent
viremia, and therefore, as constituting laboratory endpoint.
CD4+/CD8+ Lymphocyte Subpopulation Counts: Lymphocyte
subpopulation counts were performed according to the Brazilian AIDS
Consensus, every 3-4 months. Additional measurements were obtained
as necessary. Beckton-Dickinson flow cytometry kits were used with
FacsCount devices to perform this test.
HIV-1 Viral Load: HIV-1 viral loads were performed every 3-4
months, according to the Brazilian AIDS Consensus. Additional
measurements were obtained when necessary. Viral load testing was
performed using Nuclisense Biolab® (NASBA), which has a lower limit
of detection of 40 copies/mm3, according to the manufacturer’s
instructions.
Lymphoproliferative assays: Lymphoproliferative assays were
performed at least once during the study. As this assay did not constitute
part of our initial protocol, this analysis was not conducted on every
patient. Proliferation indexes equal to or greater than 3.0 were
considered positive.
In those patients returning negative results, an additional test was
performed after at least three months.
Endpoints: Laboratory endpoints were considered to consist of
two consecutive, positive, antigenemia tests or a decrease in CD4+
counts to less than 100 cells/mm3. Clinical endpoints constituted clinical
features suggestive of active CMV infection, requiring therapy with
ganciclovir or foscarnet despite antigenemia test results.
RESULTS
Thirty-five patients were included in the study. Twenty-six (74%)
were male. Mean age was 37.2 years (range 27-57, median 36 years).
Mean time elapsed from CD4+ recovery until inclusion in the protocol
was 454.3 days (range 92-1038, median 307 days). The median follow-
up time was 386.5 days (range 96-504). No follow-up was less than
360 days, except for those cases who met the endpoint criteria.
The mean CD4+ count at the startpoint was 278 cells/mm3 (range
112-684). At the end of follow-up, the mean CD4+ count was 342
cells/mm3 (range 113-755). The mean increase in CD4+ counts during
prophylaxis withdrawal was 62 cells/mm3.
Recurrence of CMV disease and other events: Two patients (A
and B) exhibited progressive neurological disease with CD4+ counts
greater than 100 cells/mm3 as described below:
On day 120 of follow-up, Patient A presented progressive
polyradiculopathy and typical CMV retinitis that led to a clinical
diagnosis of CMV disease, despite negative antigenemia tests and
negative PCR results performed on the cerebrospinal fluid. After
ganciclovir treatment, this patient recovered completely.
Lymphoproliferative assays were negative, indicating the absence of a
specific response to CMV. The CD4+ count at the time of recurrence
was 195 cells/mm3.
Patient B presented fever and progressive polyradiculopathy on
day 96 of follow-up. Therapy with ganciclovir was promptly initiated,
despite negative antigenemia test results. CMV-PCR testing in the
cerebrospinal fluid was performed two weeks after the initial evaluation,
yielding negative results. Lymphoproliferative assays were negative,
while the CD4+ count at disease onset was 181 cells/mm3. Despite
aggressive treatment, the patient died before a definitive diagnosis was
established. No autopsy was performed in the patient.
One patient exhibited ophthalmological features compatible with
immune recovery vitritis (IRV) at day 322 of follow-up (739 days after
HAART), but within two weeks evolved to complete recovery with no
need for corticosteroid treatment. CD4+ count at the onset of vitritis
was 336 cells/mm3, and the lymphoproliferative assay performed on
day 14 of follow up was positive (proliferation index = 3.0).
One patient presented a sustained decrease in CD4+ counts less than
100 cells/mm3 starting on day 237 of follow-up, and was excluded from
the study. Nevertheless, this patient was observed receiving CMV
prophylaxis, and displayed no evidence of relapse. Lymphoproliferative
assays were negative (proliferation index = 2.0) at the time of exclusion.
The CD4+ count at the end of the observation period was 159 cells/mm3.
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Antigenemia Tests: No patient returned a positive antigenemia
test during the study.
Lymphoproliferative Assays (LPA): Lymphoproliferative assays
were performed on only 26 of the initial 35 patients. The proliferation
index was greater than 3.0 in fifteen patients (57%) and below this
value in eleven patients. For the responders, the mean proliferation
index was 22.8 (range 3.0 - 154.9).
There was no correlation between LPA results and any other
immunological parameter measured. This included CD4+ and CD8+
counts before HAART, CD4+ and CD8+ counts before entrance to the
protocol, CD4+ and CD8+ counts at time of the LPA assay, CD4+ and
CD8+ counts at the end of the follow-up period, CD4+ to CD8+ ratio
(end of the follow-up period/pre-HAART), CD4+ and CD8+ difference
(end of the follow up-pre-HAART), and time elapsed with CD4+ counts
above 100 cells/mm3 until LPA was performed.
DISCUSSION
We found no evidence that antigenemia could predict the
reactivation of CMV disease in this study.
This method can be used to identify patients with a wide variety of
clinical syndromes of CMV disease in HIV patients, including retinitis,
gastrointestinal diseases; hepatobiliary diseases; encephalitis and other
neurological diseases; pneumonia and adrenalitis9.
The only patient with reactivated retinitis confirmed did not return
positive antigenemia during the follow-up period. The CMV disease
in this patient may have been due to local reactivation, rather than
systemic dissemination39. This mechanism of reactivation is not well
understood, but there is some evidence that the vascular endothelium
of the eye is not permeable to immune effector cells18,35.
Of our 35 patients, 57% were responders in CMV
lymphoproliferative assays. This is approximately the same as reported
by GERNA et al.11. However, among the 11 (43%) non-responders,
only one showed CMV relapse during follow-up. Similarly to previously
published data, we found no correlation between lymphoproliferative
assays (LPA) and total CD4+ and CD8+ counts at baseline, at protocol
inclusion, at the time of LPA assay, at the end of follow-up, and the
period in which CD4+ counts were greater than 100 cells/mm3. The
discrepancy between specific CD4+ response and LPA has been
described in two previous studies. PICCININI et al.29 reported some
discordance between lymphoproliferative responses and the presence
of CMV-specific CD4+ cells in AIDS patients29. KEANE et al.22,
comparing LPA and ELISpot, found a better correlation between the
latter and the presence of CMV-reactive T cells22. Neither technique,
detection of CMV-specific CD4+ cells or ELISpot, has been evaluated
for detecting those patients at risk of CMV disease relapse in this setting
so far.
Discontinuing CMV secondary prophylaxis required close clinical
follow-up in which laboratory data are not helpful in predicting
reactivation or new CMV disease. However, this careful follow-up is
not more costly than the regular follow-up necessary for HIV-infected
individuals presenting severe immunological damage.
We encountered only one case of IRV, in contrast to the situation
reported by KARAVELLAS et al.21. In this patient there was an
important increase in CD4+ count (126 cells/mm3 before HAART to
336 cells/mm3 during the onset of IRV) as described by JABS et al.16.
This case of IRV occurred later in the course of immune recovery than
has been previously described14,21, suggesting that this event might occur
even in patients showing long-term CD4+ response to HAART therapy.
Due to the low recurrence of CMV disease, we conclude, as previous
literature reports suggest, that the withdrawal of CMV prophylaxis is
a safe procedure in patients on HAART showing immune
recovery2,5,20,25,26,30,36,40,41,43,45.
Clinical demonstration of the impact of HAART on the natural history
of AIDS has been one of the most significant steps towards a more
complete comprehension of this disease. In the post-HAART era, we
have witnessed an important decrease in CMV disease incidence among
AIDS patients4,8,27,33,46. However, CMV infection remains an event
associated with high morbidity and mortality rates, justifying every effort
to understand the interaction between the virus and its host.
RESUMO
Retirada da terapia de manutenção para retinite por
citomegalovírus em pacientes com aids exibindo resposta
imunológica à terapia anti-retroviral altamente efetiva (HAART)
Antes da introdução da terapia anti-retroviral altamente efetiva
(HAART), a retinite por CMV era uma complicação comum em
pacientes com doença por HIV avançada e a terapia era bem
estabelecida e consistia em uma fase de indução com ganciclovir para
controlar a infecção, seguida por uma manutenção por toda a vida,
para evitar e retardar as recidivas. Para determinar a segurança da
retirada da terapia de manutenção para retinite por citomegalovírus
em pacientes com recuperação imunológica após o HAART, 35
pacientes com retinite por CMV tratados com terapia de manutenção,
com contagem de células CD4+ maiores que 100 células/mm3 por no
mínimo três meses, mas a maioria dos pacientes apresentava esses
valores por mais de seis meses e carga viral < 30.000 cópias/mL, foram
avaliados prospectivamente para a recorrência de doença por CMV. A
terapia de manutenção foi retirada na inclusão e os pacientes foram
monitorados no mínimo 48 semanas por avaliações clínicas e
oftalmológicas e pela determinação de marcadores de viremia para
CMV (antigenemia). Contagens de CD4+ e CD8+ e níveis de RNA de
HIV no plasma. Métodos linfoproliferativos foram realizados em 26/
35 pacientes. Resultados: Dos 35 pacientes incluídos no estudo,
somente um teve reativação da retinite por CMV confirmada, no dia
120 do seguimento. Nenhum paciente teve testes de antigenemia
positivos. Nenhuma correlação entre os ensaios linfoproliferativos e
contagens de CD4+ foi observada. Conclusão: Descontinuação da
terapia de manutenção para retinite por CMV é segura para aqueles
pacientes com recuperação imune quantitativa após HAART.
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